Literature DB >> 18337384

Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.

A Espinel-Ingroff1, E Canton.   

Abstract

We compared the Neo-Sensitabs tablet assay to both reference M38-A broth microdilution and disk diffusion methods for testing the susceptibility of 183 filamentous isolates to amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole. Neo-Sensitabs and disk assay inhibition zone diameters, in millimeters, were obtained on nonsupplemented Mueller-Hinton agar at 16 to 48 h. The reproducibility of zone diameters (i.e., the percentage of replicate zone diameters that were within 2 standard deviations of the means), their correlation with either MICs or minimum effective concentrations (for caspofungin only), and the categorical agreement were similar between tablet and disk assays (93 to 100% [R, >0.70] and 79 to 96%, respectively) with four of the five agents. The exceptions were the results for posaconazole tablets (R, 0.686; disk, 0.757; 84% categorical agreement for tablet and 96% for disk). These data suggest the potential value of the Neo-Sensitabs assay for testing 5-microg caspofungin and 1-microg voriconazole posaconazole tablets against all mold isolates, 8-microg itraconazole and 5-microg tablets against all mold isolates except zygomycetes, and 10-microg amphotericin B tablets against zygomycete isolates only.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337384      PMCID: PMC2395104          DOI: 10.1128/JCM.01883-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.

Authors:  M C Serrano; M Ramírez; D Morilla; A Valverde; M Chávez; A Espinel-Ingroff; R Claro; A Fernández; C Almeida; E Martín-Mazuelos
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

4.  Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

Authors:  A Espinel-Ingroff; B Arthington-Skaggs; N Iqbal; D Ellis; M A Pfaller; S Messer; M Rinaldi; A Fothergill; D L Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

5.  Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory.

Authors:  Inge Vandenbossche; Mario Vaneechoutte; Marleen Vandevenne; Thierry De Baere; Gerda Verschraegen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Detection of fluconazole-resistant Candida strains by a disc diffusion screening test.

Authors:  P Sandven
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

9.  Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

Authors:  Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

View more
  8 in total

Review 1.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

2.  Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

Authors:  M Mar Rodríguez; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

3.  Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Deanna A Sutton; Annette W Fothergill; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex.

Authors:  Valentina Salas; F Javier Pastor; M M Rodríguez; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

5.  Successful Posaconazole Therapy of Disseminated Alternariosis due to Alternaria infectoria in a Heart Transplant Recipient.

Authors:  Pavlina Lyskova; Milos Kubanek; Vit Hubka; Eva Sticova; Ludek Voska; Dana Kautznerova; Miroslav Kolarik; Petr Hamal; Martina Vasakova
Journal:  Mycopathologia       Date:  2016-11-19       Impact factor: 2.574

6.  Screening for drug-resistant Candida yeasts with chromogenic agar.

Authors:  William R Kirkpatrick; Joseph D Zimmerman; Fadi P Haikal; Michael J Broker; Erin Brockway; Annette W Fothergill; Dora I McCarthy; Thomas F Patterson; Spencer W Redding
Journal:  Med Mycol       Date:  2010-09       Impact factor: 4.076

7.  Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis.

Authors:  Kelen Fátima Dalben Dota; Marcia Edilaine Lopes Consolaro; Terezinha Inez Estivalet Svidzinski; Marcos Luciano Bruschi
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-09       Impact factor: 2.629

8.  Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.

Authors:  Faten Al-Wathiqi; Suhail Ahmad; Ziauddin Khan
Journal:  BMC Infect Dis       Date:  2013-03-06       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.